{"altmetric_id":2949600,"counts":{"readers":{"mendeley":46,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":2,"unique_users":["204567359644697","1426197813"],"posts_count":2},"blogs":{"unique_users_count":1,"unique_users":[57428],"posts_count":1},"news":{"unique_users_count":2,"unique_users":["justaforum","arzte_zeitung"],"posts_count":2},"total":{"posts_count":22},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":2},"twitter":{"unique_users_count":12,"unique_users":["Brain1878","mariovmendoza","BrainEditorial","stlegriel","eatsleepneuro","NeurologyToday","NeuroNecessity","DhanuMiskin","colmmcginnity","SNoori2012","DrEdWild","dubai_neuro"],"posts_count":15}},"selected_quotes":["Antiepileptic drug ESL may have both anticonvulsant and antiepileptogenic effects","Anticonvulsant drug ESL may hinder epilepsy development and overcome common drug resistance mechanism","Dual-purpose antiepileptic drug may help treat drug-resistant epilepsy #epilepsy","NEW CURE FOR #EPILEPSY! Researchers published study about a new dual-purpose antiepileptic drug. Discover here"],"citation":{"abstract":"In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem affecting a substantial fraction of patients. Many of the currently available antiepileptic drugs target voltage-gated sodium channels, leading to a rate-dependent suppression of neuronal discharge. A loss of use-dependent block has emerged as a potential cellular mechanism of pharmacoresistance for anticonvulsants acting on voltage-gated sodium channels. There is a need both for compounds that overcome this resistance mechanism and for novel drugs that inhibit the process of epileptogenesis. We show that eslicarbazepine acetate, a once-daily antiepileptic drug, may constitute a candidate compound that addresses both issues. Eslicarbazepine acetate is converted extensively to eslicarbazepine after oral administration. We have first tested using patch-clamp recording in human and rat hippocampal slices if eslicarbazepine, the major active metabolite of eslicarbazepine acetate, shows maintained activity in chronically epileptic tissue. We show that eslicarbazepine exhibits maintained use-dependent blocking effects both in human and experimental epilepsy with significant add-on effects to carbamazepine in human epilepsy. Second, we show that eslicarbazepine acetate also inhibits Cav3.2 T-type Ca(2+) channels, which have been shown to be key mediators of epileptogenesis. We then examined if transitory administration of eslicarbazepine acetate (once daily for 6 weeks, 150 mg\/kg or 300 mg\/kg) after induction of epilepsy in mice has an effect on the development of chronic seizures and neuropathological correlates of chronic epilepsy. We found that eslicarbazepine acetate exhibits strong antiepileptogenic effects in experimental epilepsy. EEG monitoring showed that transitory eslicarbazepine acetate treatment resulted in a significant decrease in seizure activity at the chronic state, 8 weeks after the end of treatment. Moreover, eslicarbazepine acetate treatment resulted in a significant decrease in mossy fibre sprouting into the inner molecular layer of pilocarpine-injected mice, as detected by Timm staining. In addition, epileptic animals treated with 150 mg\/kg, but not those that received 300 mg\/kg eslicarbazepine acetate showed an attenuated neuronal loss. These results indicate that eslicarbazepine potentially overcomes a cellular resistance mechanism to conventional antiepileptic drugs and at the same time constitutes a potent antiepileptogenic agent.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e93cf058f61000242e","authors":["Anna Doeser","Gesa Dickhof","Margit Reitze","Mischa Uebachs","Christina Schaub","Nuno Miguel Pires","Maria Jo\u00e3o Bonif\u00e1cio","Patr\u00edcio Soares-da-Silva","Heinz Beck"],"doi":"10.1093\/brain\/awu339","first_seen_on":"2014-12-04T12:13:54+00:00","issns":["1460-2156","0006-8950"],"journal":"Brain: A Journal of Neurology","last_mentioned_on":1445990400,"links":["http:\/\/dx.doi.org\/10.1093\/brain\/awu339","http:\/\/brain.oxfordjournals.org\/content\/early\/2014\/12\/02\/brain.awu339","http:\/\/brain.oxfordjournals.org\/content\/138\/2\/371","http:\/\/brain.oxfordjournals.org\/content\/138\/2\/371.abstract?etoc"],"pdf_url":"http:\/\/brain.oxfordjournals.org\/content\/brain\/early\/2014\/12\/02\/brain.awu339.full.pdf","pmid":"25472797","pubdate":"2015-02-01T00:00:00+00:00","publisher":"Oxford University Press","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"},{"name":"Psychology And Cognitive Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["brain","neurology"],"title":"Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/targeting-pharmacoresistant-epilepsy-epileptogenesis-dualpurpose-antiepileptic-drug"},"altmetric_score":{"score":29.8,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":29.8},"context_for_score":{"all":{"total_number_of_other_articles":8022450,"mean":6.7899936799808,"rank":279315,"this_scored_higher_than_pct":96,"this_scored_higher_than":7743290,"rank_type":"exact","sample_size":8022450,"percentile":96},"similar_age_3m":{"total_number_of_other_articles":237771,"mean":7.5681029229929,"rank":10292,"this_scored_higher_than_pct":95,"this_scored_higher_than":227468,"rank_type":"exact","sample_size":237771,"percentile":95},"this_journal":{"total_number_of_other_articles":3700,"mean":13.125877804812,"rank":316,"this_scored_higher_than_pct":91,"this_scored_higher_than":3382,"rank_type":"exact","sample_size":3700,"percentile":91},"similar_age_this_journal_3m":{"total_number_of_other_articles":84,"mean":12.15,"rank":6,"this_scored_higher_than_pct":91,"this_scored_higher_than":77,"rank_type":"exact","sample_size":84,"percentile":91}}},"demographics":{"poster_types":{"member_of_the_public":8,"researcher":1,"practitioner":1,"science_communicator":2},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":2,"Practitioners (doctors, other healthcare professionals)":1,"Members of the public":8,"Scientists":1}},"mendeley":{"by_status":{"Professor > Associate Professor":5,"Researcher":13,"Student  > Doctoral Student":6,"Student  > Ph. D. Student":7,"Other":4,"Student  > Master":5,"Student  > Bachelor":2,"Lecturer > Senior Lecturer":3,"Professor":1},"by_discipline":{"Engineering":1,"Medicine and Dentistry":13,"Neuroscience":11,"Chemistry":4,"Social Sciences":1,"Psychology":2,"Agricultural and Biological Sciences":9,"Computer Science":1,"Biochemistry, Genetics and Molecular Biology":2,"Unspecified":2}}},"geo":{"twitter":{"GB":4,"HN":1,"US":3,"AE":1},"mendeley":{"AR":1,"ZA":2,"FR":2,"CH":1}}},"posts":{"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/725263696#1","license":"public","citation_ids":[2949600],"posted_on":"2015-10-28T00:00:00+00:00","f1000_classes":["new_finding"],"f1000_score":"4"},{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/725263696","license":"public","citation_ids":[2949600],"posted_on":"2015-03-20T00:00:00+00:00","f1000_classes":["new_finding"],"f1000_score":"4"}],"news":[{"title":"Hoffnung f\u00fcr Epilepsiepatienten","url":"http:\/\/www.juraforum.de\/wissenschaft\/hoffnung-fuer-epilepsiepatienten-500772","license":"public","citation_ids":[2949600],"posted_on":"2014-12-04T11:17:38+00:00","summary":"[b]Wenn viele Nervenzellen im Gehirn gleichzeitig feuern, kommt es zu einem epileptischen Anfall. Medikamente verringern die Erregbarkeit der gest\u00f6rten Gehirnzellen \u2013 doch bei rund einem Drittel der Patienten wirken sie nicht. Forscher des Universit\u00e4tsklin","author":{"name":"Jura Forum","url":"http:\/\/www.juraforum.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/187\/normal\/Screen_Shot_2014-10-06_at_11.40.52.png?1412592073"}},{"title":"Epilepsie : Neue Hoffnung bei Medikamentenresistenz","url":"http:\/\/www.aerztezeitung.de\/medizin\/krankheiten\/neuro-psychiatrische_krankheiten\/epilepsie\/article\/875721\/epilepsie-neue-hoffnung-medikamentenresistenz.html","license":"public","citation_ids":[2949600],"posted_on":"2014-12-16T12:26:00+00:00","summary":"Forscher haben die Substanz Eslicarbazepinacetat genauer untersucht: Im Tiermodell sowie in Hirngewebe von Epilepsiepatienten wirkt es auch, wenn Resistenzen gegen g\u00e4ngige Medikamente wie Carbamazepin bestehen, teilt die Uniklinik Bonn mit.","author":{"name":"Arzte Zeitung ","url":"http:\/\/www.aerztezeitung.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/271\/normal\/Screen_Shot_2014-11-13_at_16.28.15.png?1415896127"}}],"twitter":[{"url":"https:\/\/twitter.com\/Brain1878\/status\/540492525090643969","license":"datasift","citation_ids":[2949600],"posted_on":"2014-12-04T13:07:14+00:00","author":{"name":"Brain","url":"http:\/\/brain.oxfordjournals.org","image":"https:\/\/pbs.twimg.com\/profile_images\/553178833780625410\/a3zTEdS8_normal.jpeg","description":"Brain: A Journal of Neurology. Publishing leading studies in neurological science since 1878.","id_on_source":"Brain1878","tweeter_id":"2292534031","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":6923},"tweet_id":"540492525090643969"},{"url":"https:\/\/twitter.com\/mariovmendoza\/status\/540496931966189568","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2014-12-04T13:24:45+00:00","author":{"name":"Mario Mendoza MD","image":"https:\/\/pbs.twimg.com\/profile_images\/866336458247983104\/nB1d16tu_normal.jpg","description":"Psychiatrist & Psychotherapist","id_on_source":"mariovmendoza","tweeter_id":"114580653","geo":{"lt":14.0818,"ln":-87.20681,"country":"HN"},"followers":176},"tweet_id":"540496931966189568"},{"url":"https:\/\/twitter.com\/BrainEditorial\/status\/540920039885787137","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2014-12-05T17:26:01+00:00","author":{"name":"Dimitri Kullmann","url":"http:\/\/brain.oxfordjournals.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/423804500286009344\/kbaEHjNK_normal.png","description":"Editor of Brain, a Journal of Neurology","id_on_source":"BrainEditorial","tweeter_id":"489444958","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":1118},"tweet_id":"540920039885787137"},{"url":"https:\/\/twitter.com\/stlegriel\/status\/540930675948683265","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2014-12-05T18:08:17+00:00","author":{"name":"Legriel St\u00e9phane","image":"http:\/\/pbs.twimg.com\/profile_images\/668557794153467904\/DBSpAxIV_normal.jpg","description":"Intensivist. Interests in #Electroencephalography #EEG, #Neurophysiology, #StatusEpilepticus, #CardiacArrest, #Epilepsy, #Encephalopathy, #NeurocriticalCare","id_on_source":"stlegriel","tweeter_id":"825896058","followers":234},"tweet_id":"540930675948683265"},{"url":"https:\/\/twitter.com\/eatsleepneuro\/status\/541968474222768129","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2014-12-08T14:52:08+00:00","author":{"name":"eat sleep neurology","image":"https:\/\/pbs.twimg.com\/profile_images\/797662232884588544\/KmYVqOtb_normal.jpg","description":"trench #neurologist, word wrangler, kitchen ninja, SJW princess, snarky nerd, wanderer | #resist #persist","id_on_source":"eatsleepneuro","tweeter_id":"2471537726","geo":{"lt":null,"ln":null},"followers":562},"tweet_id":"541968474222768129"},{"url":"https:\/\/twitter.com\/NeurologyToday\/status\/549928202521829376","license":"datasift","citation_ids":[2949600],"posted_on":"2014-12-30T14:01:15+00:00","author":{"name":"Neurology Today","url":"http:\/\/www.neurotodayonline.com","image":"https:\/\/pbs.twimg.com\/profile_images\/474220858295078914\/vUs3O0B__normal.png","description":"The official news source of the American Academy of Neurology, published by Wolters Kluwer.","id_on_source":"NeurologyToday","tweeter_id":"21938868","geo":{"lt":44.97997,"ln":-93.26384,"country":"US"},"followers":31318},"tweet_id":"549928202521829376"},{"url":"https:\/\/twitter.com\/Brain1878\/status\/562681134929436675","license":"datasift","citation_ids":[2949600],"posted_on":"2015-02-03T18:36:51+00:00","author":{"name":"Brain","url":"http:\/\/brain.oxfordjournals.org","image":"https:\/\/pbs.twimg.com\/profile_images\/553178833780625410\/a3zTEdS8_normal.jpeg","description":"Brain: A Journal of Neurology. Publishing leading studies in neurological science since 1878.","id_on_source":"Brain1878","tweeter_id":"2292534031","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":6923},"tweet_id":"562681134929436675"},{"url":"https:\/\/twitter.com\/NeuroNecessity\/status\/562709036282683393","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-03T20:27:43+00:00","author":{"name":"NeuroGirl","image":"http:\/\/pbs.twimg.com\/profile_images\/559783659503251456\/7RupZRwL_normal.png","description":"I don't think my fascination for Neuroscience will ever cease to exist. I am passionate about the research and the people neurological disorders effect.","id_on_source":"NeuroNecessity","tweeter_id":"2999901305","geo":{"lt":"42.3604823","ln":"-71.0595678","country":"US"},"followers":117},"tweet_id":"562709036282683393"},{"url":"https:\/\/twitter.com\/DhanuMiskin\/status\/562723092297175042","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-03T21:23:34+00:00","author":{"name":"Dhanu Miskin","image":"https:\/\/pbs.twimg.com\/profile_images\/771479448445124608\/pjha6kQR_normal.jpg","description":"Assistant Professor of Neurology, Lenox Hill Hospital, Hofstra School of Medicine #NeuroHIV #NeuroInfectiousDisease #NeuroImmunology #MultipleSclerosis","id_on_source":"DhanuMiskin","tweeter_id":"2810142926","geo":{"lt":40.78343,"ln":-73.96625,"country":"US"},"followers":60},"tweet_id":"562723092297175042"},{"url":"https:\/\/twitter.com\/stlegriel\/status\/562856728573014017","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-04T06:14:36+00:00","author":{"name":"Legriel St\u00e9phane","image":"http:\/\/pbs.twimg.com\/profile_images\/668557794153467904\/DBSpAxIV_normal.jpg","description":"Intensivist. Interests in #Electroencephalography #EEG, #Neurophysiology, #StatusEpilepticus, #CardiacArrest, #Epilepsy, #Encephalopathy, #NeurocriticalCare","id_on_source":"stlegriel","tweeter_id":"825896058","followers":234},"tweet_id":"562856728573014017"},{"url":"https:\/\/twitter.com\/colmmcginnity\/status\/562912748414447618","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-04T09:57:12+00:00","author":{"name":"Colm McGinnity","image":"https:\/\/pbs.twimg.com\/profile_images\/795916448589905920\/hJExm0fS_normal.jpg","description":"Neuro, psych & other stuff","id_on_source":"colmmcginnity","tweeter_id":"2444252211","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":33},"tweet_id":"562912748414447618"},{"url":"https:\/\/twitter.com\/BrainEditorial\/status\/563843962440806403","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-06T23:37:31+00:00","author":{"name":"Dimitri Kullmann","url":"http:\/\/brain.oxfordjournals.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/423804500286009344\/kbaEHjNK_normal.png","description":"Editor of Brain, a Journal of Neurology","id_on_source":"BrainEditorial","tweeter_id":"489444958","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":1118},"tweet_id":"563843962440806403"},{"url":"https:\/\/twitter.com\/SNoori2012\/status\/563847197062856704","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-06T23:50:22+00:00","author":{"name":"SNoori","image":"https:\/\/pbs.twimg.com\/profile_images\/709476339980439556\/CuJAvcEq_normal.jpg","id_on_source":"SNoori2012","tweeter_id":"808929529","geo":{"lt":null,"ln":null},"followers":264},"tweet_id":"563847197062856704"},{"url":"https:\/\/twitter.com\/DrEdWild\/status\/563956776690024449","license":"datasift","rt":["Brain1878"],"citation_ids":[2949600],"posted_on":"2015-02-07T07:05:48+00:00","author":{"name":"Ed Wild","url":"http:\/\/edwild.com","image":"https:\/\/pbs.twimg.com\/profile_images\/611107819274768384\/XJsnwDaY_normal.jpg","description":"Consultant Neurologist and Neuroscientist researching #HuntingtonsDisease at @UCLHD. Founded @HDBuzzFeed. No clinical advice here. Views my own.","id_on_source":"DrEdWild","tweeter_id":"290172750","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":3645},"tweet_id":"563956776690024449"},{"url":"https:\/\/twitter.com\/dubai_neuro\/status\/559960554169978880","license":"datasift","citation_ids":[2949600],"posted_on":"2015-01-27T06:26:14+00:00","author":{"name":"GNC Dubai","url":"http:\/\/www.gncdubai.com","image":"https:\/\/pbs.twimg.com\/profile_images\/484649699178061824\/x2b0gEWs_normal.jpeg","description":"Best German Healthcare in the fields: Neurology, Neurosurgery, Psychiatry, Psychology, Counselling & Biofeedback","id_on_source":"dubai_neuro","tweeter_id":"2591180204","geo":{"lt":25,"ln":55.33333,"country":"AE"},"followers":271},"tweet_id":"559960554169978880"}],"blogs":[{"title":"Eslicarbazepinacetat bei pharmakoresistenter Epilepsie","url":"http:\/\/medonline.at\/2014\/eslicarbazepinacetat-bei-pharmakoresistenter-epilepsie\/","citation_ids":[2949600],"posted_on":"2014-12-04T11:07:00+00:00","summary":"Die Substanz Eslicarbazepinacetat wirkt im Tiermodell und in Hirngewebe von therapieresistenten Epilepsiepatienten anfallsreduzierend und verhindert die Chronifizierung der Anfallsleiden.","author":{"name":"medONLINE","url":"http:\/\/medonline.at\/","description":"&ndash; Wissen und Services f&uuml;r &Auml;rztInnen"}}],"facebook":[{"title":"Targeting pharmacoresistant epilepsy and epileptogenesis with a...","url":"https:\/\/www.facebook.com\/204567359644697\/posts\/594326790668750","license":"public","citation_ids":[2949600],"posted_on":"2015-01-27T05:20:21+00:00","summary":"NEW CURE FOR #EPILEPSY! \n\nResearchers published study about a new dual-purpose antiepileptic drug. Discover here: http:\/\/ow.ly\/GMYh5 brain.oxfordjournals.org","author":{"name":"German Neuroscience Center","url":"https:\/\/www.facebook.com\/204567359644697","facebook_wall_name":"German Neuroscience Center","image":"https:\/\/graph.facebook.com\/204567359644697\/picture","id_on_source":"204567359644697"}},{"title":"Brain: 138 (2)","url":"https:\/\/www.facebook.com\/1426197813\/posts\/10155190832785089","license":"public","citation_ids":[21639877,3109379,3223142,3441639,3107172,3110754,2903500,2983073,3071173,2991658,3028366,3004070,3047620,2990830,2949600,3012752,2995752,2907261,2961974,2995814,2993024,2888398,3002146,3352661,21639885,21639887,21639888,2622442,3834268,21639890,3834221,21639892,21639894,21639895,21639897],"posted_on":"2015-01-27T10:35:20+00:00","summary":"Brain Table of Contents Alert\nVol. 138, No. 2\nFebruary 2015\nhttp:\/\/brain.oxfordjournals.org\/content\/138\/2?etoc\n\n-----------------------------------------------------------------\n Editorial\n-----------------------------------------------------------------","author":{"name":"Robert Karl Stonjek","url":"https:\/\/www.facebook.com\/1426197813","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/1426197813\/picture","id_on_source":"1426197813"}}]}}